Please assess the completion status of the following clinical trial:

Trial Title: Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Established diagnosis of DM2 = or \< 10 years~2. Age 21-65~3. BMI 27-32.~4. HBA1c ≥ 8%, on maximum treatment from primary care physician~5. At least one of the following co-morbidities on treatment: hypertension, hyperlipidaemia, micro/macro-proteinuria or ≤class I nephropathy, retinopathy.~Exclusion Criteria:~1. Subjects who had previous Bariatric surgery or extensive upper abdominal surgery~2. Pregnant subjects.~3. Nephropathy requiring dialysis~4. Subjects who are not fit for general anaesthesia.~5. Subjects who are unsuitable for RYGB for whatever reason, medical/surgical/psychological.~6. Subjects who are unwilling or possibly unable to participate in the follow up process.~7. Subjects who are reluctant to be randomised into the two study groups.~8. Subjects who suffers from unstable psychiatric illness~9. Subjects who are active substance abusers~10. Glutamic acid decarboxylase antibody positive.~11. fasting C-peptide \< 300 pmol/L

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Roux-en-Y Gastric Bypass (RYGB) (Type: ACTIVE_COMPARATOR): Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
- Best Medical Treatment (Type: ACTIVE_COMPARATOR): Anti-diabetic medications provided (Mono- or Combination- therapy):~Incretin analogues: Liraglutide up to 3 mg daily Or DPP-4 Inhibitors: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily Xenical: Up to 120 mg tds SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily Participants will also take lipids \& BP medications according to standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).